Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Posts Higher R&D Costs, Widened Loss in Q2; Inks Co-Development Pact with Ben Gurion University

NEW YORK (GenomeWeb News) - Rosetta Genomics today reported no second-quarter revenues, accompanied by a 55 percent rise in R&D spending and a 27 percent increase in net loss.
R&D spending for the three months ended June 30 increased to $1.7 million from $1.1 million in the year-ago period.
Net loss increased to $2.3 million from $1.8 million in the second quarter of 2005.
Rosetta Genomics, which went public in February, said it had around $5.4 million in cash and equivalents as of June 30.
The company's only income in the quarter, totaling $455,000, came from interest on bank deposits and marketable securities.
Separately, the company said yesterday that it has signed an agreement with Ben Gurion University, through B.G. Negev Technologies, that is focused on the development of microRNA-based therapies for "several key viruses," including the Epstein Barr and herpes simplex viruses.
"Because some viruses encode microRNAs, we believe the silencing of a viral microRNA may form the basis for a new class of drugs to treat infectious diseases," said Rosetta Genomics' CSO, Zvi Bentwich, in a statement.
Financial terms of the agreement with Ben Gurion University were not released.
In a statement today, CEO Amir Avniel said the company is advancing microRNA-based diagnostics through its pipeline and that it has recently been issued two new microRNA patents.
"We see these patent issuances as validation of our intellectual property position and believe more patents will follow in the coming months." Avniel added.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.